Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-Part Study of REC-994 in the Treatment of Adults With Symptomatic Cerebral Cavernous Malformation (CCM); Part 1: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Two Doses of REC-994; Part 2: A Long-Term Blinded Extension Clinical Trial to Evaluate Long-Term Safety Tolerability and Efficacy of REC-994

Next Previous
X
Search
Trial Profile

A Two-Part Study of REC-994 in the Treatment of Adults With Symptomatic Cerebral Cavernous Malformation (CCM); Part 1: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Two Doses of REC-994; Part 2: A Long-Term Blinded Extension Clinical Trial to Evaluate Long-Term Safety Tolerability and Efficacy of REC-994

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tempol (Primary)
  • Indications Central nervous system cavernous haemangioma
  • Focus Adverse reactions; Proof of concept
  • Acronyms SYCAMORE
  • Sponsors Recursion Pharmaceuticals

    • Most Recent Events

    • 03 Sep 2024 Results published in the Recursion Pharmaceuticals Media Release.
    • 03 Sep 2024 According to a Recursion Pharmaceuticals media release, Dr, Jan-Karl Burkhardt, MD, is Principal Investigator of this study. The company plans to present data from this trial at a forthcoming medical conference and intends to submit these data for publication in a peer reviewed scientific journal. A meeting with the FDA is anticipated as soon as practical to discuss plans for an additional clinical study.
    • 24 Jun 2024 According to a Recursion Pharmaceuticals media release, topline Phase 2 data readout expected in September 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top